Fig. 3
From: Are innovation and new technologies in precision medicine paving a new era in patients centric care?
Schematic of an integrated biologic information for a targeted therapeutic intervention. Ag, antigen; BETi, inhibitors of bromodomain and extraterminal proteins; carbo, carboplatin; CSF1, colony stimulating factor 1; CFM, cyclophosphamide; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; HDAC, histone deacetylase; HMA, hypomethylating agents; IDO, indoleamine 2,3-dioxyenase; IO, immune-oncology; LN, lymph nodes; LAG-3, lymphocyte-activation gene 3; MDSC, myeloid-derived suppressor cells; P13K, phosphoinositide 3-kinase; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; STING, stimulator of interferon genes; TIM3, T cell immunoglobulin and mucin domain 3; TME, tumor microenvironment; Treg, regulatory T cells; TLR, toll-like receptor; Wnt, wingless, int-1